Physiological situation based prediction of the adverse effects associated with molecularly-targeted drugs.
Project/Area Number |
21390041
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Medical pharmacy
|
Research Institution | The University of Tokyo |
Principal Investigator |
SUZUKI Hiroshi 東京大学, 医学部附属病院, 教授 (80206523)
|
Co-Investigator(Renkei-kenkyūsha) |
HISAKA Akihiro 東京大学, 医学部附属病院, 准教授 (80420206)
HONMA Masashi 東京大学, 医学部附属病院, 助教 (60401072)
MIURA Shougo 東京大学, 医学部附属病院, 助教 (90529182)
MIYAGAWA Kiyoshi 東京大学, 医学系研究科, 教授 (40200133)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥18,460,000 (Direct Cost: ¥14,200,000、Indirect Cost: ¥4,260,000)
Fiscal Year 2011: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2010: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
Fiscal Year 2009: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000)
|
Keywords | 癌 / 薬剤反応性 / キナーゼ / 分子標的薬 / オフ・ターゲット / 薬理学 / 薬物動態 / シグナル伝達 / 発現制御 / 生体分子 / 骨粗鬆症 / 骨芽細胞 / 破骨細胞 / 双方向シグナル / RANKL / 薬物体内動態 / 毒性 |
Research Abstract |
Various adverse effects associated with tyrosine kinase inhibitors, erlotinib or sunitinib, has been elucidated to link to the inhibition of off-target kinases, STK10 or PHKG1/2. Inhibition rate of off-target kinases under clinical concentration is potentially critical to predict the development of adverse effect.
|
Report
(4 results)
Research Products
(6 results)